|Articles|April 1, 2000

FDA DTC advertising survey released

Results of a new survey detailing the attitudes of consumers toward direct-to-consumer print and television advertising for pharmaceuticals have been released by the Food and Drug Administration's Division of Drug Marketing, Advertising and Communications.

The 58-question survey, "Attitudes and Behaviors Associated with Direct-to-Consumer (DTC) Promotion of Prescription Drugs," was conducted over the phone with the cooperation of 1,081 consumers. An additional follow-up written survey, the results of which had not been released at press time, looked at consumer recognition of 12 direct-to-consumer advertising campaign.

The survey revealed that 30% of consumers who have seen a doctor in the last three months, and 39% of consumers who have not seen a doctor in the last month read none of the fine print information in print DTC drug ads. However, 70% of consumers who were "especially interested" in an advertised drug would read all of the information as opposed to the 2% to 3% who would read none of the fine print.

Advertising influenced roughly half the respondents to look for more information about the drug advertised or their personal health, but only 27% of those who had seen a doctor in the last three months and 8% of those who had not seen a doctor in the last three months were ever prompted by an advertisement to "ask a doctor about a medical condition or illness of [their] own that they had not talked to a doctor about before."

Full results of the survey, which also looked at how consumers perceived their doctors' reactions to queries about advertised prescription drugs, are available at www.fda.gov/cder/ddmac/dtcindex.htm#Q1. PR


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.